Rituximab is approved by the Food and Drug Administration (FDA) to be used alone or with other drugs to treat certain types of B-cell non-Hodgkin lymphoma. It is also approved to be used with methotrexate to treat rheumatoid arthritis. Rituximab is also being studied in the treatment of other types of cancer and other conditions.
Researchers determine the risk of COVID-19 and possibility of severe sequelae in patients with systemic lupus erythematosus and the general population.
A new report throws light on SARS-CoV-2 breakthrough infections in patients with certain joint diseases or musculoskeletal conditions who are on rituximab and compares the severity of COVID-19 outcomes in these patients whilst identifying potential risk factors for severe outcomes.
Researchers conducted a comparative study among a cohort of individuals on rheumatoid arthritis (RA) therapies vis-à-vis healthy controls to assess their responses to coronavirus disease 2019 (COVID-19) vaccines.
Late-breaking research reveals a major treatment advance for adults with newly diagnosed B lineage acute lymphoblastic leukemia (ALL).
A third COVID-19 vaccine dose in this patients with blood cancers could enhance their antibody responses against SARS-CoV-2
New research presented this week at ACR Convergence 2022, the American College of Rheumatology's annual meeting, showed that a higher dose of pneumococcal vaccine safely and effectively improved antibody response in patients receiving rituximab for ANCA-associated vasculitis.
In a new study, researchers assessed the remdesivir resistance developed in coronavirus disease 2019 (COVID-19)-infected transplant recipients.
Early intervention with rituximab, a drug used in the treatment of rheumatoid arthritis (RA), can reduce the risk of deterioration in myasthenia gravis, an autoimmune disease that causes loss of muscle control.
A new study published in the CDC's Morbidity and Mortality Weekly Report analyzed two people with encephalomyelitis associated with monkeypox disease in Colorado and DC during the current outbreak.
In a recent study published in the journal BMJ Open, researchers investigated the impact of folic acid supplements and methotrexate, in combination or individually, on disease severity and mortality in coronavirus disease 2019 (COVID-19) cases.
Researchers examined immune reactions to SARS-CoV-2)among B cell-depleted autoimmune patients who concomitantly administered glucocorticoids.
A new study has reported two renal transplant cases, in which individuals, after being exposed to remdesivir, developed a resistance to the drug.
There is considerable variation in the management of mantle cell lymphoma across different clinical settings, and some strategies do not always conform with what might be expected, according to an analysis by investigators from Weill Cornell Medicine and other leading health institutions.
In a recent study posted to the medRxiv* pre-print server, researchers in Israel described the case of a severely immunocompromised cancer patient who developed a chronic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
Researchers assessed the risk of severe COVID-19 in adults with immune-mediated inflammatory diseases and those on immunomodulatory therapies.
Combination chemoimmunotherapy with the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib demonstrated improved progression-free survival over standard chemoimmunotherapy for previously untreated mantle cell lymphoma (MCL) in patients 65 and over, researchers from The University of Texas MD Anderson Cancer Center reported today at the 2022 American Society of Clinical Oncology Annual Meeting.
Genetically engineered immune cells successfully target the specific cancer cells that may be responsible for relapse of acute myeloid leukemia (AML), a type of blood cancer, and proved effective in animal models of the disease, according to a preclinical study by investigators at Weill Cornell Medicine.
New research from Queen Mary University of London, published in Nature Medicine, has shown that molecular profiling of the diseased joint tissue can significantly impact whether specific drug treatments will work to treat rheumatoid arthritis (RA) patients.
MS patients treated with Rituximab have better responses to the COVID-19 vaccine if they have higher B cell counts.
Researchers investigated the interplay of all the factors responsible for within-host evolution of SARS-CoV-2 variants in immunocompromised patients.